Chinese Drug Regulator Accepts Marketing Application of Humanwell Healthcare's Unit for Pregabalin Tablets

MT Newswires Live

09/01

China's National Medical Products Administration accepted the drug registration and marketing authorization application of Humanwell Healthcare's (SHA:600079) unit, Yichang Humanwell Pharmaceutical, for pregabalin extended-release tablets, according to a Shanghai bourse filing on Tuesday.

The drug is used to treat neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia.

The pharmaceutical company invested 62 million yuan into the research and development of the drug.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2664336068"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2664336068\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2664336068?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-01 13:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2664336068","market":"sg","top_or_hot":-1,"title":"Chinese Drug Regulator Accepts Marketing Application of Humanwell Healthcare's Unit for Pregabalin Tablets","media":"MT Newswires Live","content":"<html><body><p> China's National Medical Products Administration accepted the drug registration and marketing authorization application of <a href=\"https://laohu8.com/S/600079\">Humanwell Healthcare</a>'s (SHA:600079) unit, Yichang Humanwell Pharmaceutical, for pregabalin extended-release tablets, according to a Shanghai bourse filing on Tuesday.</p><p>The drug is used to treat neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia.</p><p>The pharmaceutical company invested 62 million yuan into the research and development of the drug.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Chinese Drug Regulator Accepts Marketing Application of Humanwell Healthcare's Unit for Pregabalin Tablets</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChinese Drug Regulator Accepts Marketing Application of Humanwell Healthcare's Unit for Pregabalin Tablets\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2026-09-01 13:39</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> China's National Medical Products Administration accepted the drug registration and marketing authorization application of <a href=\"https://laohu8.com/S/600079\">Humanwell Healthcare</a>'s (SHA:600079) unit, Yichang Humanwell Pharmaceutical, for pregabalin extended-release tablets, according to a Shanghai bourse filing on Tuesday.</p><p>The drug is used to treat neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia.</p><p>The pharmaceutical company invested 62 million yuan into the research and development of the drug.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"600079","symbol_name":"ST人福","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2664336068","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2664336068","pubTimestamp":1788241159,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"China's National Medical Products Administration accepted the drug registration and marketing authorization application of Humanwell Healthcare's  unit, Yichang Humanwell Pharmaceutical, for pregabalin extended-release tablets, according to a Shanghai bourse filing on Tuesday.The drug is used to treat neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia.The pharmaceutical company invested 62 million yuan into the research and development of the drug.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600079":"ST人福","BK4581":"高盛持仓","LU0128526141.USD":"TEMPLETON GLOBAL SMALLER COMPANIES \"A\" ACC","XLV":"健康照护类股ETF-SPDR","BK0028":"国家队","XBI":"SPDR S&P Biotech ETF","LU0029874061.USD":"TEMPLETON GLOBAL SMALLER COMPANIES \"A\" YDIS INC","BK0185":"二线龙头","LABU":"三倍做多标普生物-Direxion","BK0239":"医药制造","BK4137":"综合支持服务","BK0012":"证金概念","BK0070":"员工持股","HCSG":"Healthcare Svcs Group Inc","BK0188":"融资融券","BK4585":"ETF&股票定投概念","BK4588":"碎股","BK0096":"民营医院"},"translate_title":"中国药品监管部门受理人福医药普瑞巴林片单位上市申请","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600079":0.9,"HCSG":1.5,"LABU":0.6,"XLV":1.5,"XBI":0.6},"content_text":"China's National Medical Products Administration accepted the drug registration and marketing authorization application of Humanwell Healthcare's (SHA:600079) unit, Yichang Humanwell Pharmaceutical, for pregabalin extended-release tablets, according to a Shanghai bourse filing on Tuesday.The drug is used to treat neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia.The pharmaceutical company invested 62 million yuan into the research and development of the drug.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}